Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
PR Newswire•13/10/2026•07:00 ET
0
Key Highlights
- ➤AbbVie acquired Apogee for over $10.9 billion in 2026.
- ➤Former Apogee executives joined Paragon to lead clinical development and operations.
- ➤Alaunos (TCRT) completed its acquisition of Velaris Therapeutics.
- ➤Velaris brings ActRII-Fc ligand traps and complementary biologics targeting pulmonary hypertension.
- ➤Velaris is Paragon’s ninth company launched around discovered assets.
Expert Statements
Michael Henderson, M.D., Chief Executive Officer of Paragon Labs
“At Apogee, we learned a tremendous amount about what it takes to translate Paragon-discovered programs into clinical-stage medicines. We now have an opportunity to apply those lessons to clinical development, regulatory strategy and execution from the very start, as Paragon's programs take shape. That means bringing all of these insights to make decisions even earlier, so the companies that license Paragon's most promising assets can bring them to patients even faster.”
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc. PR Newswire
Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie
Get started
Create a free account to read the full story.